Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is a commercial-stage medical device and biopharmaceutical company that has developed the LungFit platform, which uses nitric oxide generated from ambient air to treat various diseases, including neurological and neuro-oncology indications, viral pneumonia, and cancer. Their recent encouraging data from the Beyond Cancer segment and a proposed transaction to monetize the NeuroNOS platform could potentially bring significant value to the company and its shareholders in the future. Additionally, the consistent revenue growth shown in the US LungFit market also indicates potential for success and growth in the future.

Bears say

Beyond Air is facing a challenging market as they attempt to commercialize their LungFit platform and diversify their revenue streams. Despite a recent leadership change and promising revenue growth, the company's over-reliance on LungFit and a failed attempt to sell their NeuroNOs subsidiary highlights potential risks and weaknesses in their strategy. While Beyond Air still has potential for growth, investors may want to approach with caution until the company can demonstrate proven success in diversifying their business and improving go-to-market execution.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.